Review Papers Claim by Claim

Visual summary — core strengths & weaknesses

Visual: evidence coverage (counts)

Detailed critique — organized

1) Scope & organization

Clear scope: broad fungal taxa and AMP classes; organized by fungal genus (Malassezia, Trichophyton, Candida, Aspergillus, Cryptococcus, Mucorales, etc.) and by AMP family (defensin, cathelicidin, histatin, RNase, lactoferrin, dermcidin, hepcidin). Useful tables (Table 1) list AMP sources and reported targets. The review functions well as a reference index for researchers entering antifungal AMP research. Strength: breadth and modern referencing (2024–2025 literature included).

2) Evidence quality and interpretation

The review accurately reports primary literature (in vitro MICs, some animal-model results) but — as acknowledged by the authors — comparing MICs across studies is fraught (different media, salts, inocula, endpoints). Zhang et al. correctly warn against over-extrapolation from in vitro MICs to clinical efficacy. Where the review goes further is by summarizing engineering strategies (truncation, cyclization, D-amino acid substitution, cyclopeptides, dendrimers, nanoparticles) and citing exemplar translational studies. These synthesis points are the paper’s strongest practical contribution.

3) Mechanisms & theory

Zhang et al. review both membrane-active mechanisms (carpet, barrel-stave, toroidal pores) and intracellular targeting leading to ROS/mitochondrial dysfunction and apoptosis-like death in fungi — summarizing consistent mechanistic motifs from multiple sources (e.g., LL-37 pore formation, histatin-5 cytoplasmic entry, HBD2 PIP2-mediated permeabilization). This is a faithful synthesis of the literature and helpful to anyone designing mechanism-driven experiments.

4) Translational assessment — what the review gets right

• Correctly identifies proteolytic degradation and salt sensitivity as central barriers to systemic AMP therapy.
• Accurately emphasizes topical/local applications (nail, skin, cornea) as nearer-term clinical opportunities — supported by examples such as NP213/Novexatin (dermatophyte candidate) and dendrimer/nanoformulations in the literature.
• Discusses rational engineering (D-amino acids, cyclization, end-capping, conjugation to carriers) and combination therapy (AMPs + standard antifungals) as credible strategies to improve potency and reduce toxicity.

5) What is missing or under-emphasized

1. Quantitative meta-synthesis. The review does not attempt meta-analysis or standardized re-scoring of MICs across studies — understandable for a narrative review but a missed opportunity to provide harmonized effect-size estimates or a recommendation for standard assay conditions.
2. Host-safety risk quantification. Discussion of hemolysis and cytotoxicity is qualitative; the field would benefit from standardized therapeutic-index thresholds (e.g., HC50/MIC) as decision rules for translational progression.
3. Resistance-risk modeling. Little is said about whether fungi can evolve AMP resistance clinically and what cross-resistance mechanisms (cell wall remodeling, proteases, efflux) are most concerning; recent modeling and experimental evolution studies could have been cited to strengthen this point.

6) Conflicts, funding, and bias assessment

The authors declare no conflicts of interest and list NSFC funding. The review acknowledges publication bias and assay heterogeneity as limitations. As with all narrative reviews, selection bias remains possible; the authors’ transparent funding and COI statement is appropriate.

Practical recommendations for researchers (concise)

1. Standardize in vitro antifungal assays for AMP studies (report salt, inoculum, growth phase, planktonic vs biofilm, serum) to allow cross-study meta-analysis.
2. Report therapeutic index metrics (HC50 or CC50 / MIC) and proteolytic half-life in serum/plasma for any lead peptide candidate.
3. Prioritize topical/locally delivered indications (onychomycosis, keratitis, skin) for early trials where delivery/stability barriers are smaller.
4. Perform systematic resistance-evolution experiments (serial passage) to quantify the likelihood and mechanisms of fungal AMP resistance.
5. Use combination screens (AMP + azole/polyene/echinocandin) to identify reproducible synergies and reduced resistance emergence.

Confidence & summary statement

Overall assessment: This is a high-quality, current narrative review that will be useful as a reference and roadmap for antifungal AMP research; it correctly frames both promise and practical obstacles. Key missing elements (meta-analysis, resistance-evolution data, standardized TI reporting) provide clear next steps to increase field rigor.

Actionable next steps (for BGPT Premium user)

• Run a targeted meta-analysis: compile MICs and HC50/CC50 from the primary studies tabulated in Zhang et al., harmonize assay conditions, compute weighted TI estimates and highlight candidates meeting TI thresholds (e.g., TI > 10).
• Design in vivo topical proof-of-concept (nail/skin/cornea) for top AMP candidates with controlled PK/proteolysis arms (PEGylation, D-residues, nanoparticle conjugates) and pre-specified toxicity readouts.
• Run experimental evolution experiments to quantify fungal resistance trajectories to candidate AMPs and AMP+azole combinations.

Author review quick-links